FDA Approves Exact Sciences’ Cologuard Plus Test for Colorectal Cancer Screening
HCPLive
OCTOBER 4, 2024
The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.
Let's personalize your content